HomeCompareCHDGF vs ABBV

CHDGF vs ABBV: Dividend Comparison 2026

CHDGF yields 7.97% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHDGF wins by $100313.07M in total portfolio value
10 years
CHDGF
CHDGF
● Live price
7.97%
Share price
$0.88
Annual div
$0.07
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$100313.18M
Annual income
$97,952,376,421.90
Full CHDGF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CHDGF vs ABBV

📍 CHDGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHDGFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHDGF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHDGF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHDGF
Annual income on $10K today (after 15% tax)
$677.51/yr
After 10yr DRIP, annual income (after tax)
$83,259,519,958.61/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CHDGF beats the other by $83,259,498,902.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHDGF + ABBV for your $10,000?

CHDGF: 50%ABBV: 50%
100% ABBV50/50100% CHDGF
Portfolio after 10yr
$50156.64M
Annual income
$48,976,200,596.83/yr
Blended yield
97.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CHDGF
No analyst data
Altman Z
6.7
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHDGF buys
0
ABBV buys
0
No recent congressional trades found for CHDGF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHDGFABBV
Forward yield7.97%3.06%
Annual dividend / share$0.07$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$100313.18M$102.3K
Annual income after 10y$97,952,376,421.90$24,771.77
Total dividends collected$100151.97M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHDGF vs ABBV ($10,000, DRIP)

YearCHDGF PortfolioCHDGF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,294$1,594.13$11,550$430.00+$744.00CHDGF
2$16,818$3,663.26$13,472$627.96+$3.3KCHDGF
3$27,362$9,366.77$15,906$926.08+$11.5KCHDGF
4$57,762$28,484.63$19,071$1,382.55+$38.7KCHDGF
5$174,201$112,395.98$23,302$2,095.81+$150.9KCHDGF
6$819,982$633,587.04$29,150$3,237.93+$790.8KCHDGF
7$6,451,878$5,574,496.72$37,536$5,121.41+$6.41MCHDGF
8$88,888,335$81,984,826.05$50,079$8,338.38+$88.84MCHDGF
9$2,206,354,041$2,111,243,521.68$69,753$14,065.80+$2206.28MCHDGF
10$100,313,175,245$97,952,376,421.90$102,337$24,771.77+$100313.07MCHDGF

CHDGF vs ABBV: Complete Analysis 2026

CHDGFStock

COSCO SHIPPING International (Hong Kong) Co., Ltd., an investment holding company, provides shipping services in the People's Republic of China and internationally. The company's Coatings segment produces and sells coatings products, including container, industrial heavy-duty anti-corrosion, and marine coatings. Its Marine Equipment and Spare Parts segment sells and installs equipment and spare parts for existing and new build vessels, as well as equipment of radio communications systems, satellite communications, and navigation systems for ships, offshore facilities, coastal stations and land users; supplies marine material; and provides voyage repair services. The company's Ship Trading Agency segment offers agency services relating to shipbuilding, ship trading, and bareboat chartering for second-hand and obsolete vessels; consultancy services for ship technology and trading; business negotiations for purchasing of new build; purchase and sale contract of second hand vessels; follow-ups of the construction; and delivery process of new build ships. Its Insurance Brokerage segment provides insurance and reinsurance intermediary services of marine and non-marine insurance. The company's Marine Fuel and Other Products segment engages in the supply, trading, and brokerage services of marine fuel and related products. Its General Trading segment is involved in the trading, storage, processing, and supply of asphalt; trading of various vessel spare parts and accessories; and other comprehensive trading. The company was formerly known as COSCO International Holdings Limited and changed its name to COSCO SHIPPING International (Hong Kong) Co., Ltd. in November 2016. The company was incorporated in 1992 and is headquartered in Central, Hong Kong. COSCO SHIPPING International (Hong Kong) Co., Ltd. is a subsidiary of COSCO SHIPPING (Hong Kong) Co., Limited.

Full CHDGF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CHDGF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHDGF vs SCHDCHDGF vs JEPICHDGF vs OCHDGF vs KOCHDGF vs MAINCHDGF vs JNJCHDGF vs MRKCHDGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.